Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00705835
Recruitment Status : Completed
First Posted : June 26, 2008
Last Update Posted : January 9, 2012
PSMA Development Corp, LLC
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : January 2008
  Study Completion Date : January 2008